Immuno-Oncology

Nivolumab/Ipilimumab Efficacy in Clear Cell RCC May Be Tied to Certain Immune-Cell Related Parameters

February 22, 2022

Patients with 4-1BB or LAG-3–expressing T cells at baseline, or a high proportion of PD-L1–expressing myeloid cells and plasmacytoid dendritic cells during boost cycles, may be more likely to benefit from the combination of nivolumab and ipilimumab.